Amanote Research
Register
Sign In
Prm242 - Using Non-Randomised Evidence or Clinical Assumptions to Make Connections in Network Meta-Analysis - A Case Study in Relapsed/Refractory Multiple Myeloma
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.2360
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
Y Guo
S Rabar
M Rizzo
Publisher
Elsevier BV
Related search
Carfilzomib for Relapsed or Refractory Multiple Myeloma
The Lancet Oncology
Oncology
Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma
European Journal of Medical Research
Medicine
Atacicept in Relapsed/Refractory Multiple Myeloma or Active Waldenström's Macroglobulinemia: A Phase I Study
British Journal of Cancer
Cancer Research
Oncology
A Phase I Clinical Study of Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study
American Journal of Hematology
Hematology
Arsenic Trioxide-Based Therapy in Relapsed/Refractory Multiple Myeloma Patients: A Meta-Analysis and Systematic Review
OncoTargets and Therapy
Oncology
Pharmacology
Carfilzomib Monotherapy in Japanese Patients With Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study
Cancer Science
Cancer Research
Medicine
Oncology
Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Optimizing the Use of Lenalidomide in Relapsed or Refractory Multiple Myeloma: Consensus Statement
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
